Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LINEBACKER LB2
- Development stage
- Preclinical
- Lead developer
- ProPhase Labs
- Modality
- Small Molecules
- Administration
- Unknown
01
Overview
**LINEBACKER LB2** is a patented, investigational small molecule based on **di-chlorinated myricetin**, a modified plant-derived flavonoid, developed as part of the Linebacker platform. The modification involves chlorine atoms substituted for hydroxy groups at two positions on the myricetin scaffold. The primary mechanism of action is the inhibition of **PIM kinases**, serine/threonine kinases that function as oncogenes or mediators in cancer and inflammatory diseases. LB2 is being explored for its **anti-cancer** and **anti-inflammatory** properties, with potential in other therapeutic areas such as infectious diseases (notably ZIKA, malaria, and influenza) and neurodegenerative and memory-related diseases including Alzheimer’s disease. The Linebacker compounds were originally developed by Global BioLife, Inc. in partnership with GRDG Sciences before being licensed for worldwide development and commercialization by ProPhase BioPharma, a subsidiary of ProPhase Labs[1][3][4].
- Brand names
- LINEBACKER LB2
- Other names
- LB-2LB2LB 2Di-chlorinated Myricetin
02
Targets
PIM1 (Proviral integration site for moloney murine leukemia virus kinase 1)
Beyond the preview
Go deeper on LINEBACKER LB2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LINEBACKER LB2.